173 related articles for article (PubMed ID: 33853503)
1. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Rattarittamrong E; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e915-e921. PubMed ID: 35792033
[TBL] [Abstract][Full Text] [Related]
3. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
Kolla BC; Halim NAA; Cao Q; Sachs Z; Warlick E; Weisdorf D; Ho AYL; Chuan WG; Lao Z; He F
Br J Haematol; 2021 Jul; 194(1):140-144. PubMed ID: 33843048
[TBL] [Abstract][Full Text] [Related]
4. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
Vale CA; Egan PC; Ingham R; Farmakiotis D; Reagan JL
Ann Hematol; 2021 Jan; 100(1):79-84. PubMed ID: 32870366
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
[TBL] [Abstract][Full Text] [Related]
8. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
9. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
Shepshelovich D; Edel Y; Goldvaser H; Dujovny T; Wolach O; Raanani P
Br J Clin Pharmacol; 2015 Apr; 79(4):685-91. PubMed ID: 25303309
[TBL] [Abstract][Full Text] [Related]
11. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
Ochs MA; Perissinotti AJ; Marini BL; Burke PW; Bixby DL; Pettit KM; Benitez LL
Leuk Res; 2021 Mar; 102():106517. PubMed ID: 33561633
[TBL] [Abstract][Full Text] [Related]
12. The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
Chen G; Yang J; Cao F; Zhou W; Gong D; Liu L; Zhou D
Ann Transl Med; 2022 Aug; 10(16):858. PubMed ID: 36111020
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Miyamoto T; Nagafuji K; Fujisaki T; Uchida N; Matsue K; Henzan H; Ogawa R; Takase K; Aoki T; Hidaka M; Teshima T; Taniguchi S; Akashi K; Harada M;
Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
[TBL] [Abstract][Full Text] [Related]
14. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.
Ravikumar D; Saju H; Choudary A; Bhattacharjee A; Dubashi B; Ganesan P; Kayal S
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):31-41. PubMed ID: 35125710
[TBL] [Abstract][Full Text] [Related]
16. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Sperr WR; Herndlhofer S; Gleixner K; Girschikofsky M; Weltermann A; Machherndl-Spandl S; Sliwa T; Poehnl R; Buxhofer-Ausch V; Strecker K; Hoermann G; Knoebl P; Jaeger U; Geissler K; Kundi M; Valent P
Am J Hematol; 2017 Oct; 92(10):E567-E574. PubMed ID: 28699225
[TBL] [Abstract][Full Text] [Related]
17. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
Ciftciler R; Demiroglu H; Buyukasık Y; Okay M; Aksu S; Sayınalp N; Malkan UY; Haznedaroglu IC; Ozcebe O; Goker H
Transfus Apher Sci; 2018 Dec; 57(6):752-755. PubMed ID: 30249531
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
[TBL] [Abstract][Full Text] [Related]
19. Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.
Shpilberg O; Haddad N; Sofer O; Raanani P; Berkowicz M; Chetrit A; Carter A; Ramot B; Tatarski I; Ben-Bassat I
Leuk Res; 1995 Dec; 19(12):893-7. PubMed ID: 8632657
[TBL] [Abstract][Full Text] [Related]
20. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
